Madrigal Pharmaceuticals Stock Skyrockets 200% After Positive Results for its Drug to Treat “Silent Disease”

0
100

Madrigal is aiming to file for accelerated approval for resmetirom in the first half of 2023.

 

 

Signup for the USA Herald exclusive Newsletter